FDA Priority Review Granted to Garetosmab for FOP
Rare Disease Biologic Advances Toward U.S. Approval – February 19, 2026 | Tarrytown, New York Regeneron Pharmaceuticals announced that...
Orphan Drug
Advertisement
SENTI-202 AML Cell Therapy Completes Phase 1 Enrollment
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 — Senti Biosciences announced the completion of patient enrollment in its Phase...
Ifetroban Gains FDA Fast Track for DMD Heart Disease
NASHVILLE, Tenn., Feb. 4, 2026 —Cumberland Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has granted Fast...
Apecotrep Shows 40% Proteinuria Reduction in Phase II FSGS Trial
Ingelheim, Germany | January 29, 2026 — Boehringer Ingelheim announced positive results from a 12-week Phase II clinical trial...
Omeros Details FDA Approval Path for First TA-TMA Therapy
SEATTLE, Dec. 26, 2025 — Omeros Corporation has announced a revised date for its upcoming conference call to discuss...
Advertisements
Sharp Therapeutics Strengthens Path to Gaucher Trials
December 19, 2025 | Pittsburgh, Pennsylvania and Toronto, Ontario — Sharp Therapeutics Corp. has announced an updated non-brokered private...
Vicore Pharma Advances to Nasdaq Mid Cap Segment
Stockholm, Sweden, December 19, 2025 — Vicore Pharma Holding AB (publ) announced that it will move from the Nasdaq...
FDA Reviews New Data to Advance SL1009 for Rare PDCD
ROSWELL, Ga., DUBLIN & HAMILTON, Bermuda — December 9, 2025 — Saol Therapeutics announced that the U.S. Food and...
Cardiol Therapeutics Gains Major Patent Boost for Heart Drugs
NEW YORK, November 13, 2024 — Cardiol Therapeutics has secured a U.S. patent allowance protecting its next-generation cardiac therapies...
Pharvaris Unveils Breakthrough Oral Therapy for HAE Relief
ZUG, Switzerland, November 10, 2025 — Pharvaris N.V. (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor...
Advertisement
